BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Ernest Poku is moving to Bayer Leverkusen and has signed a contract with Erik ten Hag’s team until mid-2030. The 21-year-old ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Bayer has recently settled thousands of cases over claims the active ingredient in its Roundup weedkiller causes cancer, ...

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...

Bayer (BAYRY) stock falls as the company's better-than-expected Q2 2025 results are overshadowed by a disappointing ...